Abstract: Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.

Abstract: The present disclosure includes compositions and methods for treating cancer, such as bladder cancer.

Abstract: We have modified a commercially-available adherent cell culture bioreactor in several ways to increase productivity of cultured cells, while decreasing contamination risk. We found that modifying a commercially-available adherent cell culture bioreactor to provide for slower cell culture medium flow unexpectedly and dramatically increases the productivity of the cultured adherent cells. We also developed a new sampling manifold configuration and new way of taking samples, to reduce contamination risk.

Abstract: The present invention relates to the treatment of cardiovascular diseases. In particular the present invention relates to micro RNA (mi RNA) molecules for use in the regulation of the gene expression of Vascular endothelial growth factor A (VEGFA), Vascular endothelial growth factor D (VEGFD) and/or Hypoxia-inducible factor 1-alpha (HIF1A) in a variety of applications, including use in therapeutic and diagnostic applications. VEGFA has diverse functions in both developing and mature individuals. VEGFA is a well-known critical regulator of angiogenesis and is also involved in the development and metastasizing of cancer.

Abstract: We have modified a commercially-available adherent cell culture bioreactor in several ways to increase productivity of cultured cells, while decreasing contamination risk. We found that modifying a commercially-available adherent cell culture bioreactor to provide for slower cell culture medium flow unexpectedly and dramatically increases the productivity of the cultured adherent cells. We also developed a new sampling manifold configuration and new way of taking samples, to reduce contamination risk.

Abstract: We have modified a commercially-available adherent cell culture bioreactor, developing a new sampling manifold configuration and new way of taking samples to reduce contamination risk.

Abstract: Producing adenovirus gene therapy vector in producer cells that express or over-express adenoviral polypeptide IX enables one to produce pIX-deleted adenovirus in suspension cell culture. Using producer cells that express or over-express adenoviral polypeptide IX also increases the yield of adenovirus vector, regardless of whether that adenovirus is pIX-deleted. Using producer cells that express or over-express adenoviral polypeptide IX also improves the resulting vector's transduction kinetics, reducing the number of pfu/target cell required to achieve a given level of transduction/infection, shortening the time the vector requires to transduce or infect a target cell, and shortening the time an infected target cell produces progeny virus.

Abstract: Novel forward primer, reverse primer and poly-linker suitable for replication of nucleic acids in e.g., 293 cells.

Abstract: Viral gene therapy provides a successful treatment for high-grade, non-muscle invasive bladder cancer resistant to, or recurrent after, treatment with intravesical bacillus Calmette-Guérin (BCG) vaccine. Our therapy provides the first and only way to reliably curtail the progression of superficial, non-muscle invasive cancer into more lethal muscle-invasive cancer.

Abstract: A viral gene therapy combination therapy for cancer, using a virus to deliver a gene to a human patient, where the gene expresses a polypeptide which is not native to the wild-type virus, yet which is nonetheless therapeutically useful when administered in combination with a chemotherapeutic agent.

Abstract: Novel forward primer, reverse primer and poly-linker suitable for replication of nucleic acids in e.g., 293 cells.

Abstract: We have found a counter-intuitive way to improve the commercial-scale production of recombinant biological products in adherent-cell bioreactors, which reduces the risk of cell culture contamination, increases total yield and reduces the delay between seeding and harvest, thus minimizing expression product degradation, by inter alia inoculating an adherent culture bioreactor with suspension-adapted producer cells.

Abstract: Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.

Abstract: A method of treating brain cancer in an immune-competent human patient by administering ternozolornide to the immune-competent human patient, the improvement comprising administering to said immune-competent human patient a viral vector.

Abstract: We have found a counter-intuitive way to improve the commercial-scale production of recombinant biological products in adherent-cell bioreactors, which reduces the risk of cell culture contamination, increases total yield and reduces the delay between seeding and harvest, thus minimizing expression product degradation, by inter alia inoculating an adherent culture bioreactor with suspension-adapted producer cells

Abstract: A high-volume gene therapy vector manufacturing process which produces a recombinant gene therapy vector which is able to transform host cells even when they are not dividing.

Abstract: A high-volume gene therapy vector manufacturing process, entailing using a recombinant baculovirus to transform a producer cell, which producer cell in turn produces a recombinant gene therapy vector which is able to transform host cells even when they are not dividing.

Abstract: Gene therapy with genes for prodrug converting enzymes adds to local control of glioblastoma achieved by surgery. There appears to be a pronounced local reaction which is in part inflammatory and has a measurable immunological component. Considering the widely proven fact that during the weekslong gap-phase between surgery and completion of radiation or chemoradiation tumour growth from the infiltrative zone may continue unhampered, a treatment such as SIT will cover that time period.

Abstract: Anti-angiogenic gene therapy with a combination of soluble Vascular Endothelial Growth Factors (sVEGFR) improves the efficacy of chemotherapy with paclitaxel for reducing ovarian cancer mean tumor volume (in cubic millimetres) as measured using magnetic resonance imaging. The study groups were: AdLacZ control, combination of AdsVEGFR-1, -2 and -3, combination of AdsVEGFR-1, -2, -3 and paclitaxel, bevacizumab monotherapy, paclitaxel monotherapy and carboplatin monotherapy. Effectiveness was assessed by survival time and surrogate measures such as sequential MRI, immunohistochemistry, microvessel density and tumor growth. Antiangiogenic gene therapy combined with paclitaxel significantly prolonged the mean survival compared to the controls and all other treatment groups (p=0.001). Tumors of the mice treated by gene therapy were significantly smaller than in the control group (p=0.021). The mean vascular density and total vascular area were also significantly smaller in the tumors of the gene therapy group (p=0.

Abstract: Treating cancer of a organ located in a mesothelium-lined body cavity (i.e., lung, kidney, adrenal gland, ovary, prostate, pancreas or bladder cancer) by irrigating the mesothelium-lined body cavity with a solution containing a recombinant viral gene therapy vector bearing an interferon transgene, optionally administered shortly before administering chemotherapy and/or COX-2 inhibitor.